skip to Main Content

Respiratory Syncytial Virus Infection in Preterm Infants: Six Seasons; Experience in an Integrated Health Care Delivery System

We will study the impact of the change in the American Academy of Pediatrics’s palivizumab recommendations in a large cohort of infants (300,000) of all gestations over a 7-year period (2010- 2016). We will quantify and characterize the following over this period: 1) occurrence of bronchiolitis in children 24 months of age; 2) testing patterns for Respiratory Syncytial Virus (RSV); 3) RSV immunoprophylaxis utilization; and 4) health care utilization among infants and children with RSV infection, with particular emphasis on hospitalization and use of intensive care.

Investigator: Escobar, Gabriel

Funder: AstraZeneca PLC

Explore all studies and publications

Back To Top